Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/22/03/06 | Sickle Cell Disease A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease |
Principal Investigator(s) 1. Janet Oyieko 2. Fredrick Chite Asirwa 3. Bernhards Ogutu Site(s) in Kenya 1. Kombewa Clinical Research Centre (Kisumu county) 2. Victoria Biomedical Research institute (Kisumu county) 3. International Cancer Centre (Uasin Gishu county) 4. CREATES - Strathmore University Medical Centre (Nairobi City county) |
15-09-2022 |
View |
52. |
ECCT/22/06/02 | Mitapivat - AG348-C-020 A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. |
Principal Investigator(s) 1. Lucas Otieno Tina 2. Bernhards Ragama Ogutu 3. Prof Jessie N Githanga 4. Videlis N Nduba 5. Janet N/A Oyieko 6. Allan Godfrey Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Strathmore University Medical Centre (Nairobi City county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. Gertrude’s Children’s Hospital (Nairobi City county) 6. KEMRI Kondele Children\'s Hospital (Kisumu county) 7. Kombewa Clinical Research Centre (Kisumu county) |
06-09-2022 |
View |
53. |
ECCT/22/05/03 | Anti-malaria MAb in Kenyan chi Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya |
Principal Investigator(s) 1. Titus Kwambai 2. Laura Steinhardt 3. Robert A Seder Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Kogelo Health Center (Siaya county) |
08-08-2022 |
View |
54. |
ECCT/22/03/04 | VIBRI COVID-19-001/2021 A Multi-Centre, Randomized, Double Blind, Phase 2b Trial to Evaluate the Safety and Immunogenicity of Janssen Ad26COVS1 and Novavax NVX-CoV2373 COVID-19 vaccines for Homologous and Heterologous Boosting in Adolescents and Adults Aged 12 to 64 Years with and without HIV infection in 3 African Countries (Kenya, Democratic Republic of Congo, and Rwanda). |
Principal Investigator(s) 1. Dr. Lucas Otieno Tina Site(s) in Kenya Victoria Biomedical Research Institute, |
04-05-2022 |
View |
55. |
ECCT/21/10/03 | Validation of Chloe SED Validation of Chloe SED, a reusable, low-cost syringe extension device for the provision of paracervical analgesia during gynecologic procedures |
Principal Investigator(s) 1. Stephen Gwer Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county) 2. Kisii Teaching & Referral Hospital (KTRH) (Kisii county) |
29-04-2022 |
View |
56. |
ECCT/22/01/02 | CoVPN 3008 Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern |
Principal Investigator(s) 1. Ben Madeke Andagalu Site(s) in Kenya 1. KEMRI -USAMRD-A, Kombewa Clinical Research Centre (Kisumu county) 2. KEMRI-CGHR (Kisumu county) |
14-04-2022 |
View |
57. |
ECCT/21/06/11 | Pulse oximeter use in labour The use of Fetal Pulse Oximetry in determining fetal wellbeing during labour: A non-randomized clinical trial |
Principal Investigator(s) 1. Felix Mwembi Oindi Site(s) in Kenya Aga Khan University hospital |
10-02-2022 |
View |
58. |
ECCT/21/11/05 | SOLIDARITY TRIAL PLUS An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care |
Principal Investigator(s) 1. loice Ombajo Site(s) in Kenya 1. KENYATTA NATIONAL HOSPITAL SITE (Nairobi City county) 2. The Nairobi Hospital (Nairobi City county) |
13-01-2022 |
View |
59. |
ECCT/21/09/03 | Women TDF/FTC Benchmark Study Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya KEMRI-CCR PHRD (THIKA) PROJECT |
19-12-2021 |
View |
60. |
ECCT/21/07/02 | TALIOS A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
01-11-2021 |
View |